After drinking a sugary solution, people with early kidney disease who took pravastatin had no meaningful difference in their blood sugar two hours later compared to those who took a sugar pill.
Scientific Claim
In non-diabetic patients with chronic kidney disease stages 1–3, pravastatin at 40 mg/day for 12 weeks does not significantly affect 2-hour post-oral glucose tolerance test plasma glucose levels, with a mean difference of −0.6 mmol/L (95% CI −1.3 to 0.1, P=0.10) compared to placebo.
Original Statement
“Mean 2-h P-glucose following an OGTT was 7.0 mmol/l (SEM ±0.9) and 5.4 mmol/l (SEM ±0.3) following treatment with Pravastatin and placebo, respectively, with a non-significant difference between treatments of −0.6 mmol/l (SE ±0.3, 95% CI −1.3 to 0.1, P = 0.10).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
RCT design supports causal inference, but the p-value is borderline and sample size is small. The claim appropriately uses 'does not significantly affect' and avoids definitive language.
More Accurate Statement
“In non-diabetic patients with chronic kidney disease stages 1–3, pravastatin at 40 mg/day for 12 weeks likely does not significantly affect 2-hour post-oral glucose tolerance test plasma glucose levels, with a mean difference of −0.6 mmol/L (95% CI −1.3 to 0.1, P=0.10) compared to placebo.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether pravastatin consistently has no effect on postprandial glucose in CKD populations across multiple studies.
Whether pravastatin consistently has no effect on postprandial glucose in CKD populations across multiple studies.
What This Would Prove
Whether pravastatin consistently has no effect on postprandial glucose in CKD populations across multiple studies.
Ideal Study Design
Meta-analysis of RCTs using OGTT 2-hour glucose as primary outcome in non-diabetic CKD stages 1–3 patients treated with pravastatin 40 mg/day vs. placebo, minimum 12-week duration, total n≥500.
Limitation: Cannot assess individual variability or long-term metabolic consequences.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of pravastatin on postprandial glucose response in CKD patients.
Causal effect of pravastatin on postprandial glucose response in CKD patients.
What This Would Prove
Causal effect of pravastatin on postprandial glucose response in CKD patients.
Ideal Study Design
Double-blind RCT of 200+ non-diabetic CKD stage 1–3 patients randomized to pravastatin 40 mg/day vs. placebo for 24 weeks, with standardized 75g OGTT performed at baseline and endpoint, measuring 2-hour glucose as primary outcome.
Limitation: Does not capture effects on insulin secretion or beta-cell function beyond glucose levels.
Prospective Cohort StudyLevel 2bLong-term association between pravastatin use and postprandial glucose dysregulation leading to prediabetes.
Long-term association between pravastatin use and postprandial glucose dysregulation leading to prediabetes.
What This Would Prove
Long-term association between pravastatin use and postprandial glucose dysregulation leading to prediabetes.
Ideal Study Design
Prospective cohort of 1000+ non-diabetic CKD stage 1–3 patients followed for 5 years, with annual OGTT and comparison of 2-hour glucose trajectories between pravastatin users and non-users, adjusting for diet, activity, and eGFR.
Limitation: Cannot establish causation due to potential confounding.
Evidence from Studies
Supporting (1)
The study gave people with early kidney disease pravastatin for 12 weeks and checked their blood sugar after drinking a sugary drink — just like the claim said. It found no real change in blood sugar, so the claim is right.